The Innovative Health Initiative will see the scope of joint research between industry, academics and SMEs expand beyond pharmaceuticals, to include medical technology, biotech, digital health and vaccines
It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton
It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?